Orphazyme A S ADR (NASDAQ: ORPH) announced 24-month temporary consequences of an open-label extension (OLE) pilot, providing effectiveness and security statistics for its new treatment arimoclomol in Niemann-Pick disease type C (NPC) for up to 36 months.  Data was presented at Parseghian Scientific Conference for NPC Research The statistics are […]